Protein aggregation and its impact on product quality

Area of Science:

• Biopharmaceutical science
• Protein chemistry
• Drug development

Background:

• Protein therapeutics, like monoclonal antibodies, are vital in modern medicine.
• Proteins can exist in various aggregated states, influencing drug efficacy and safety.
• Understanding protein aggregation is crucial for pharmaceutical product quality.

Purpose of the Study:

• To review the mechanisms and reasons behind protein aggregate formation.
• To discuss the impact of protein aggregates on pharmaceutical product quality and performance.
• To outline fundamental and practical strategies for controlling protein aggregation in the industry.

Main Methods:

• Literature review of scientific publications and industry practices.
• Analysis of the impact of different protein aggregated states.
• Synthesis of information on aggregate control strategies.

Main Results:

• Protein aggregation can be beneficial or detrimental to drug products.
• Various factors contribute to the formation of protein aggregates.
• Effective strategies exist for managing and controlling protein aggregation.

Conclusions:

• Controlling protein aggregation is essential for ensuring the quality and performance of protein-based pharmaceuticals.
• A comprehensive understanding of aggregation mechanisms informs the development of robust control strategies.
• Industry practices focus on mitigating deleterious aggregation for therapeutic success.